Echo360's GoReact and Macmillan Learning Expand Partnership to Deliver AI-Powered Authentic Assessment at Scale
According to the National Association of Colleges and Employers (NACE) Job Outlook 2024, 73.3% of employers rated oral and written communication as very or extremely important for new graduates. Yet only 47.5% felt that students were proficient in these skills—highlighting a major gap. This expanded partnership gives instructors in communication courses a powerful tool to help close that gap through personalized, immediate feedback.
The integration of the AI Assistant in GoReact into Macmillan Learning's Achieve platform gives instructors a trusted, efficient way to deliver targeted feedback faster that helps students practice, reflect, and build critical skills.
Using the power of video, GoReact enables students to practice and demonstrate skill mastery from anywhere, review their performance or share it with others for feedback. With the AI Assistant in GoReact, learners and instructors are instantly provided with personalized AI feedback, enabling the student to reflect, identify areas for improvement, and build both confidence and competence through practice.
'Macmillan Learning has been one of our most innovative partners and this partnership is purpose-built to reimagine teaching and learning in a skills-first world. We couldn't be more excited to expand our partnership,' said Jeff Peterson, Global Chief Growth and Marketing Officer at Echo360. 'Macmillan Learning is committed to putting powerful, practical AI tools in the hands of instructors not just for efficiency, but to truly support student growth and skill development.'
In 2017, Macmillan Learning became the first major digital learning company to integrate video-based assessment tools from GoReact. With the power of AI and the global scale and reach of Echo360's Echosystem, that foundation is poised for continued growth, meeting the demands of learners and their expectations for the skills they need for the workplace.
'Today's students need more than knowledge, they also need the confidence and communication skills to succeed in the real world. By bringing tools like GoReact into Achieve, we're helping instructors deliver the kind of personalized, skills-based feedback that prepares learners for life beyond the classroom,' said Susanne Jeans, Macmillan Learning Program Director.
About GoReact
GoReact, now part of Echo360's Echosystem™, simplifies skills-based learning and assessment by providing more chances to practice, reflect and evaluate progress using the power of video. By providing evidence of competency, along with personalized feedback and AI-enabled tools, GoReact elevates skill development that transforms potential into mastery. More than 800 academic institutions and companies worldwide use GoReact to enable skill development. See how GoReact helps all learners build skills for a brighter future at www.GoReact.com.
Macmillan Learning is a privately-held, family-owned company that inspires what's possible for every learner. We envision a world in which every learner succeeds. Through our content, tools and services, we aim to make that a reality. To learn more, please visit macmillanlearning.com or join our Community.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
a few seconds ago
- Yahoo
ZyVersa Therapeutics Reports Second Quarter 2025 Financial Results and Highlights Key Near-term Value-building Milestones
KEY HIGHLIGHTS First clinical site for Phase 2a clinical trial for Cholesterol Efflux Mediator™ VAR 200 in patients with diabetic kidney disease (DKD) was activated June 2025; patient screening is underway, with interim results expected ~Q4-2025. IND-enabling obesity preclinical study with Inflammasome ASC Inhibitor IC 100 in a diet-induced obesity (DIO) animal model planned to begin ~Q4-2025. Invited MJFF grant request submitted for funding Parkinson's disease animal model proof-of-concept studies; response expected Q3-2025. Raised approximately $2.05 million since the end of Q2-2025; $4.05 million year-to-date. WESTON, Fla., Aug. 13, 2025 (GLOBE NEWSWIRE) -- ZyVersa Therapeutics, Inc. (OTCQB: ZVSA, or 'ZyVersa'), a clinical-stage specialty biopharmaceutical company developing first-in-class drugs for treatment of patients with renal and inflammatory diseases who have unmet medical needs, reports financial results for the quarter ended June 30, 2025, and highlights progress toward achieving key value-building milestones. 'I am pleased to announce that we are well positioned to achieve our near-term development milestones,' said Stephen C. Glover, ZyVersa's Co-founder, Chairman, CEO, and President. "In June and July 2025, we closed two financing transactions providing access to $12 million in capital to advance development of our highly differentiated drug therapies for kidney and inflammatory diseases, each of which target untargeted pathways to advance care for these serious conditions. Regarding our kidney disease drug VAR 200, in mid-June we initiated an open-label Phase 2a trial in patients with DKD. VAR 200 uniquely targets lipid accumulation in the kidney's filtration system that triggers inflammation, fibrosis, and progressive kidney damage leading to renal failure if not addressed. Preliminary data are expected in Q4-2025, with final results anticipated H1-2026. The data will provide insights for developing a larger Phase 2a/b protocol in patients with FSGS, our lead indication. Based VAR 200's unique mechanism of action, we were asked and agreed to provide drug and regulatory support under FDA-authorized Emergency Compassionate Use to treat a patient at the University of Miami Miller School of Medicine who has ApoCII amyloidosis, a very rare, life-threatening disease which mainly affects the kidney. Concerning our inflammasome inhibitor IC 100, we are making progress toward IND submission. Preparation is underway with the University of Miami School of Medicine to initiate an IND-enabling preclinical study in a diet-induced obesity (DIO) animal model in Q4-2025. A phase 1 trial in overweight healthy subjects at risk for certain cardiometabolic conditions will be initiated shortly following IND clearance. IC 100 uniquely targets inhibition of the ASC inflammasome component rather than the NLRP3 sensor molecule. By targeting ASC, IC 100 uniquely inhibits multiple inflammasome pathways and their associated ASC specks to alleviate perpetuation and spread of inflammation that damages tissues and organs causing numerous diseases and their progression. We appreciate your support for our efforts to develop groundbreaking drugs to improve patients' health and quality of life.' PIPELINE UPDATE Cholesterol Efflux Mediator™ VAR 200 Kidney Disease (Global Drug Market: $18 Billion in 2024; $30 Billion Projected by 2034) The first patient is expected to be treated in a phase 2a clinical trial in patients with DKD in Q3-2025, with interim results in Q4-2025. The intent of the study is to obtain renal patient proof-of-concept for VAR 200 prior to initiating a larger phase 2a/b for VAR 200's lead indication, FSGS. The DKD study will evaluate VAR 200's safety and efficacy (% change in proteinuria from baseline to week 12) in eight patients with type 2 diabetes who have diabetic kidney disease. Inflammasome ASC Inhibitor IC 100 Inflammatory Diseases (Global Biologics Market: $105 Billion in 2024; $186 Billion Projected by 2034) Obesity with Cardiometabolic Complications In preparation for filing an IND for IC 100, a diet-induced obesity (DIO) mouse model study is expected to be initiated in partnership with University of Miami Miller School of Medicine Q4-2025. The study will evaluate the effects of IC 100 on body weight, body composition, and changes in cardiovascular, metabolic, and inflammatory parameters in comparison to semaglutide, and when administered concurrently with semaglutide. Following IND clearance, a phase 1 trial will be initiated with IC 100 in healthy overweight people (BMI: 27 – 30) at risk of cardiometabolic conditions to evaluate the safety of 3 different doses of IC 100, and to get a signal on the degree of weight loss, and changes in cardiometabolic biomarkers that can be expected with each dose. Second Quarter 2025 FINANCIAL RESULTS Cash on hand was $0.1 million as of June 30, 2025. On July 8, 2025, we closed a $2.05M warrant inducement transaction from a current investor. Research and development expenses were $0.4 million for the three months ended June 30, 2025, a decrease of $0.3 million or 42.2% from the three months ended June 30, 2024. The decrease is attributable to lower CRO fees of $0.1 million for VAR 200, lower research and development consultant costs of $0.1 million resulting from fewer consultants, and lower pre-clinical costs of $0.1 million for IC 100, partially offset by an increase in VAR 200 manufacturing stability testing. General and administrative (G&A) expenses were $1.6 million for the three months ended June 30, 2025, a decrease of $0.4 million or 20.1% from the three months ended June 30, 2024. The decrease is primarily attributable to a decrease of $0.1 million in director and officer insurance premiums, a $0.1 million decrease in investor and public relations marketing expense, a $0.1 million decrease in professional fees from lower accounting and legal expense, and a decrease of $0.1 million in stock-based compensation expense resulting from fully amortized options in 2025. Decreased G&A expenses were partially offset by a $0.1 million increase in public company costs due to additional costs associated with our annual shareholder meeting and Nasdaq hearings. Net losses were approximately $2.2 million for the three months ended June 30, 2025, with an improvement of $0.6 million or 20% compared to a net loss of approximately $2.8 million, for the three months ended June 30, 2024. Based on our current operating plan, we expect our cash and cash equivalents will only be sufficient to fund operating expenses and capital expenditure requirements on a month-to-month basis. ZyVersa will need additional financing to support its continuing operations, pay for its current liabilities, and to meet its stated milestones. ZyVersa will seek to fund its operations and clinical activity through public or private equity, debt financings, or other sources which may include government grants, collaborations with third parties, or outstanding warrant exercises. ABOUT ZYVERSA THERAPEUTICS, INC. ZyVersa (OTCQB: ZVSA) is a clinical stage specialty biopharmaceutical company leveraging advanced, proprietary technologies to develop first-in-class drugs for patients with renal and inflammatory diseases who have significant unmet medical needs. The Company is currently advancing a therapeutic development pipeline with multiple programs built around its two proprietary technologies – Cholesterol Efflux Mediator™ VAR 200 for treatment of kidney diseases, and Inflammasome ASC Inhibitor IC 100, targeting damaging inflammation associated with numerous CNS and peripheral inflammatory diseases. For more information, please visit CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS Certain statements contained in this press release regarding matters that are not historical facts, are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These include statements regarding management's intentions, plans, beliefs, expectations, or forecasts for the future, and, therefore, you are cautioned not to place undue reliance on them. No forward-looking statement can be guaranteed, and actual results may differ materially from those projected. ZyVersa Therapeutics, Inc. ('ZyVersa') uses words such as 'anticipates,' 'believes,' 'plans,' 'expects,' 'projects,' 'future,' 'intends,' 'may,' 'will,' 'should,' 'could,' 'estimates,' 'predicts,' 'potential,' 'continue,' 'guidance,' and similar expressions to identify these forward-looking statements that are intended to be covered by the safe-harbor provisions. Such forward-looking statements are based on ZyVersa's expectations and involve risks and uncertainties; consequently, actual results may differ materially from those expressed or implied in the statements due to a number of factors, including ZyVersa's ability to obtain the funding necessary to advance the development of our product candidates and maintain its business operations; plans to develop and commercialize its product candidates, the timing of initiation of ZyVersa's planned preclinical and clinical trials; the timing of the availability of data from ZyVersa's preclinical and clinical trials; the timing of any planned investigational new drug application; ZyVersa's plans to research, develop, and commercialize its current and future product candidates; the clinical utility, potential benefits and market acceptance of ZyVersa's product candidates; ZyVersa's commercialization, marketing and manufacturing capabilities and strategy; ZyVersa's ability to protect its intellectual property position; and ZyVersa's estimates regarding future revenue, expenses, capital requirements and need for additional financing. New factors emerge from time-to-time, and it is not possible for ZyVersa to predict all such factors, nor can ZyVersa assess the impact of each such factor on the business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Forward-looking statements included in this press release are based on information available to ZyVersa as of the date of this press release. ZyVersa disclaims any obligation to update such forward-looking statements to reflect events or circumstances after the date of this press release, except as required by law. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities. CORPORATE, MEDIA, IR CONTACT Karen CashmereChief Commercial Officerkcashmere@ ZYVERSA THERAPEUTICS, CONSOLIDATED BALANCE SHEETS June 30,2025 December 31,2024 (Unaudited) Assets Current Assets: Cash $ 72,086 $ 1,530,924 Prepaid expenses and other current assets 378,749 184,873 Vendor deposits 98,234 - Total Current Assets 549,069 1,715,797 In-process research and development 18,647,903 18,647,903 Vendor deposit 69,477 178,476 Deferred offering costs 374,662 57,238 Total Assets $ 19,641,111 $ 20,599,414 Liabilities and Stockholders' Equity Current Liabilities: Accounts payable $ 9,774,230 $ 9,337,267 Accrued expenses and other current liabilities 2,915,448 1,894,041 Total Current Liabilities 12,689,678 11,231,308 Deferred tax liability 851,659 851,659 Total Liabilities 13,541,337 12,082,967 Stockholders' Equity: Preferred stock, $0.0001 par value, 1,000,000 shares authorized: Series A preferred stock, 8,635 shares designated, 50 shares issued and outstanding as of June 30, 2025 and December 31, 2024 - - Series B preferred stock, 5,062 shares designated, 5,062 shares issued and outstanding as of June 30, 2025 and December 31, 2024 1 1 Common stock, $0.0001 par value, 250,000,000 shares authorized; 4,873,463 and 2,508,198 shares issued as of June 30, 2025 and December 31, 2024, respectively, and 4,873,456 and 2,508,191 shares outstanding as of June 30, 2025 and December 31, 2024, respectively 487 251 Additional paid-in-capital 123,207,260 121,155,922 Accumulated deficit (117,100,806 ) (112,632,559 ) Treasury stock, at cost, 7 shares at June 30, 2025 and December 31, 2024 (7,168 ) (7,168 ) Total Stockholders' Equity 6,099,774 8,516,447 Total Liabilities and Stockholders' Equity $ 19,641,111 $ 20,599,414 ZYVERSA THERAPEUTICS, CONSOLIDATED STATEMENTS OF OPERATIONS(Unaudited) For the Three Months Ended June 30, 2025 2024 Operating Expenses: Research and development $ 409,937 $ 709,049 General and administrative 1,634,195 2,044,929 Total Operating Expenses 2,044,132 2,753,978 Loss From Operations (2,044,132 ) (2,753,978 ) Other (Income) Expense: Interest expense 130,036 58 Change in fair value of equity payable 37,149 - Pre-Tax Net Loss (2,211,317 ) (2,754,036 ) Income tax benefit - (9,707 ) Net Loss $ (2,211,317 ) $ (2,763,743 ) Net Loss Per Share - Basic and Diluted $ (0.46 ) $ (3.31 ) Weighted Average Number of Common Shares Outstanding - Basic and Diluted 4,814,115 834,915
Business Wire
2 minutes ago
- Business Wire
Firstsource and Guidehealth Partner to Accelerate AI-Enabled Value-Based Care Innovation for Health Plans
MUMBAI, India & DALLAS--(BUSINESS WIRE)-- Firstsource Solutions Limited (NSE:FSL, BSE:532809), a leading global provider of business management services and an RP-Sanjiv Goenka Group company, today announced a strategic partnership with Guidehealth – a pioneer in quality outcomes and value-based care innovation. This collaboration will empower health plans to deliver measurable value for members and providers by accelerating the adoption of next-generation, outcome-driven care models and preventive care. Firstsource's AI-first approach – recognized as a 'Front-Runner' in Generative AI for Healthcare Payers by Everest Group – combines deep domain expertise with its proprietary relAI™ suite and UnBPOᵀᴹ transformation model to help health plans move beyond incremental change. By embedding AI into operations, Firstsource enables streamlined processes, enhanced member engagement, and better health outcomes through intelligent, interoperable platforms that drive agility and measurable results. Guidehealth brings a proven track record in value-based care innovation, helping payers and providers shift to models that reward quality, efficiency, and improved patient outcomes. By combining advanced analytics, clinical expertise, and AI-integrated workflows, Guidehealth supports the implementation and optimization of Medicare Advantage Stars and value-based arrangements – delivering >4 Star performance and measurable improvements in care coordination, cost control, and member satisfaction within the first year. Venkatgiri Vandali, Head, Healthcare & Lifesciences, Firstsource, shared, 'This partnership marks a pivotal step in our mission to redefine healthcare operations. We're proud to support Guidehealth's bold vision for value-based care – uniting their innovation with Firstsource's AI-first, UnBPOᵀᴹ model. By integrating intelligent automation, deep domain expertise, and a human-first mindset, we're enabling health plans to deliver smarter, more personalized, and outcomes-driven care at scale. Together, we're orchestrating a new era of healthcare transformation.' Sanjay Doddamani, MD & CEO, Guidehealth, said, 'Guidehealth is committed to making great healthcare affordable for all by advancing value-based care by combining AI and empathy and delivering tech-enabled healthcare services across the healthcare system. Partnering with Firstsource enables us to combine our expertise in care delivery with cutting-edge AI and digital platforms, creating a powerful ecosystem for health plans and providers. We are excited to deliver measurable value for our clients and their network of doctors and patients.' Firstsource and Guidehealth will offer health plans a comprehensive suite of solutions that: Accelerate successful value-based care adoption through AI, advanced analytics, and clinical expertise Streamline claims and care management using automation and data-driven insights to ensure timely, appropriate care and operational efficiency Enhance member engagement and performance by delivering personalized, tech-enabled experiences that drive measurable improvements in MA Stars, cost, and clinical outcomes across the healthcare value chain Together, Firstsource and Guidehealth offer a powerful, tech-enabled partnership that blends operational excellence with clinical insight. Their combined capabilities help clients transform healthcare delivery at scale – accelerating digital maturity, improving health outcomes, and driving performance in a value-based care environment. About Firstsource Firstsource Solutions Limited, an RP-Sanjiv Goenka Group company (NSE: FSL, BSE: 532809, Reuters: Bloomberg: FSOL:IN), is a global leader providing transformational solutions and services spanning the customer lifecycle across Healthcare, Banking and Financial Services, Communications, Media and Technology, Retail, and other diverse industries. With a global footprint across US, UK, India, Philippines, Mexico, Romania, Turkey, Trinidad & Tobago, South Africa, and Australia, we 'make it happen' for our clients, solving their biggest challenges with hyper-focused, domain-centered teams and cutting-edge tech, data, and analytics. Our inch-wide, mile-deep practitioners work collaboratively, leveraging UnBPO™ - our differentiated approach to reimagining traditional outsourcing - to deliver real-world, future-focused solutions that drive speed, scale, and smarter decision, turning transformation into tangible results for our clients. ( About Guidehealth Guidehealth is dedicated to making great healthcare affordable for all. The company partners with health systems and clinical networks to bring scale and predictable performance to value-based care across all lines of business. Led by physicians, Guidehealth augments existing primary care capacity using innovative AI-based protocols, remotely embedded Healthguides™, and a meticulously designed framework to predict those patients most in need of support in and beyond the exam room. For more information, visit
Business Wire
2 minutes ago
- Business Wire
KIOXIA Advances AI Server Infrastructure Scalability, Accelerating Storage Performance and Density
SAN JOSE, Calif.--(BUSINESS WIRE)-- KIOXIA America, Inc. today announced high-capacity, high-efficiency data storage solutions designed to support AI-scale workloads and reduce power and cooling requirements with Dell Technologies. Leveraging KIOXIA LC9 Series 245.76 terabyte (TB) NVMe™ SSDs, Dell systems enable organizations to manage multi-petabyte data sets and modernize their infrastructure to support generative AI and machine learning applications. 'SSDs like the KIOXIA LC9 Series combined with Dell PowerEdge servers offer high-capacity, power-efficient solutions tailored for advanced AI workloads while optimizing TCO and data center footprints.' KIOXIA LC9 Series SSDs deliver up to 245.76 TB of flash-based storage with PCIe ® 5.0 performance in high-density form factors, including 2.5-inch, E3.S, and E3.L. They offer a compelling alternative to an equivalent capacity of traditional hard disk drives (HDDs), which have limited performance and can have higher operational costs. By replacing multiple HDDs per slot, KIOXIA LC9 Series SSDs better utilize GPUs, free up drive bays, and reduce cooling requirements. This results in a more efficient use of space and power, enabling organizations to scale AI infrastructure without expanding their physical footprint or energy consumption. 'Together, Dell Technologies and KIOXIA have a long history of enabling scalable infrastructure for data-driven applications,' said Arun Narayanan, senior vice president, Compute and Networking, Dell Technologies. 'SSDs like the KIOXIA LC9 Series combined with Dell PowerEdge servers offer high-capacity, power-efficient solutions tailored for advanced AI workloads while optimizing TCO and data center footprints.' Built with KIOXIA BiCS FLASH™ generation 8 3D flash memory using 32-die QLC stacking and innovative CBA (CMOS directly Bonded to Array) technology, the KIOXIA LC9 Series enables compact, large-capacity SSDs ideal for the demands of AI infrastructure—from training large language models (LLMs) to powering inference pipelines like retrieval augmented generation (RAG). 'Enterprises today are pushing the limits of their data center infrastructure to stay competitive in the AI era,' said Neville Ichhaporia, senior vice president and general manager of the SSD business unit at KIOXIA America, Inc. 'With our KIOXIA LC9 Series SSDs, together with Dell Technologies we're removing storage bottlenecks, driving higher rack-density and enabling more sustainable, scalable systems that make the most of every GPU and each watt of power.' KIOXIA LC9 Series NVMe SSD Key Features Include: Industry's first 1 245.76 TB SSD, utilizing KIOXIA BiCS FLASH™ generation 8, 32-die stack QLC memory packages Designed for AI applications and data lakes Capacities starting at 30.72 TB and up to 245.76 TB Designed to PCIe 5.0 and NVMe 2.0 specifications Available in 2.5-inch, E3.S and E3.L form factors Dual port for server and high-availability storage systems This continued collaboration builds on more than two decades of innovation between KIOXIA and Dell Technologies. Together, the companies have delivered storage industry milestones, including the first enterprise deployments of PCIe 5.0 EDSFF E3.S 2, 24G SAS 3, and Value SAS 4 technologies. The KIOXIA LC9 Series 245.76 TB SSD was featured in a live demo at the Future of Memory and Storage 2025, August 5-7, 2025. For more information, please visit and follow the company on X, formerly known as Twitter and LinkedIn ®. About KIOXIA America, Inc. KIOXIA America, Inc. is the U.S.-based subsidiary of KIOXIA Corporation, a leading worldwide supplier of flash memory and solid-state drives (SSDs). From the invention of flash memory to today's breakthrough BiCS FLASH™ 3D technology, KIOXIA continues to pioneer innovative memory, SSD and software solutions that enrich people's lives and expand society's horizons. The company's innovative 3D flash memory technology, BiCS FLASH, is shaping the future of storage in high-density applications, including advanced smartphones, PCs, automotive systems, data centers and generative AI systems. For more information, please visit © 2025 KIOXIA America, Inc. All rights reserved. Information in this press release, including product pricing and specifications, content of services, and contact information is current and believed to be accurate on the date of the announcement, but is subject to change without prior notice. Technical and application information contained here is subject to the most recent applicable KIOXIA product specifications. Notes: Definition of SSD capacity: KIOXIA Corporation defines a kilobyte (KB) as 1,000 bytes, a megabyte (MB) as 1,000,000 bytes, a gigabyte (GB) as 1,000,000,000 bytes, a terabyte (TB) as 1,000,000,000,000 bytes, and a kibibyte (KiB) is 1,024 bytes. A computer operating system, however, reports storage capacity using powers of 2 for the definition of 1GB = 2^30 bytes = 1,073,741,824 bytes and 1TB = 2^40 bytes = 1,099,511,627,776 bytes and therefore shows less storage capacity. Available storage capacity (including examples of various media files) will vary based on file size, formatting, settings, software and operating system, and/or pre-installed software applications, or media content. Actual formatted capacity may vary. The flash memory capacity is calculated as 1 terabit (1 Tb) = 1,099,511,627,776 (2^40) bits, and 1 terabyte (1 TB) = 1,099,511,627,776 (2^40) bytes. 2.5-inch indicates the form factor of the SSD and not its physical size. Read and write speed may vary depending on various factors such as host devices, software (drivers, OS etc.), and read/write conditions. Dell Technologies, Dell, and other trademarks are trademarks of Dell Inc. or its subsidiaries. NVMe and NVMe-MI are registered or unregistered trademarks of NVM Express, Inc. in the United States and other countries. PCIe is a registered trademark of PCI-SIG. LinkedIn is a trademark of LinkedIn Corporation and its affiliates in the United States and/or other countries. Other company names, product names and service names may be trademarks of third-party companies.
